Hearing loss associated with paromomycin treatment in a patient with visceral leishmaniasis

Hearing loss associated with paromomycin treatment in a patient with visceral leishmaniasis

Bibliographic Details
Main Authors:	Rocio Asensi-Diez, David Furones Araujo, Carmen Gallego Fernández
Format:	Article
Language:	English
Published:	Grupo Aula Médica 2017-05-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/10760.pdf

Similar Items

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
by: Wiwanitkit V
Published: (2012-06-01)

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review
by: Pashupati Pokharel, et al.
Published: (2021-01-01)

Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
by: Prabhat K. Sinha, et al.
Published: (2011-01-01)

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.
by: Kazi M Jamil, et al.
Published: (2015-01-01)

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.
by: Ahmed M Musa, et al.
Published: (2010-10-01)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
by: Ridwanur Rahman, et al.
Published: (2017-05-01)

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
by: Asrat Hailu, et al.
Published: (2010-10-01)

Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
by: Ahmed Musa, et al.
Published: (2012-01-01)

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
by: Shabi Parvez, et al.
Published: (2020-07-01)

Effectiveness of Paromomycin on Cutaneous Leishmaniasis in Iran: A Systematic Review and Meta-Analysis
by: Rahmatollah Moradzadeh, et al.
Published: (2019-05-01)

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
by: Dae Hyun Kim, et al.
Published: (2009-01-01)

Treatment of visceral leishmaniasis
by: E M Moore, et al.
Published: (2010-01-01)

Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment
by: Ander Burgaña, et al.
Published: (2019-12-01)

Visceral Leishmaniasis Treatment, Italy
by: Luigi Gradoni, et al.
Published: (2003-12-01)

Glomerulopathy Associated with Visceral leishmaniasis
by: Sh Khademvatan, et al.
Published: (2007-06-01)

Glomerulopathy Associated with Visceral leishmaniasis
by: Sh Khademvatan, et al.
Published: (2007-03-01)

Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani.
by: Bhavna Chawla, et al.
Published: (2011-01-01)

The Treatment of Visceral Leishmaniasis: Safety and Efficacy
by: Rajesh Kumar Jha, et al.
Published: (2013-12-01)

Recent understanding in the treatment of visceral leishmaniasis.
by: Rosenthal E, et al.
Published: (2003-01-01)

The Treatment of Visceral Leishmaniasis: Safety and Efficacy
by: Rajesh Kumar Jha, et al.
Published: (2013-12-01)

Visceral leishmaniasis treatment outcome and associated factors in northern Ethiopia
by: K. Gidey
Published: (2020-12-01)

Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia
by: Kidu Gidey, et al.
Published: (2019-01-01)

Monoclonal gammopathy associated with visceral leishmaniasis
by: Vishal Sharma, MD, et al.
Published: (2010-05-01)

Monoclonal gammopathy associated with visceral leishmaniasis
by: Vishal Sharma, et al.

Intraretinal hemorrhage associated with visceral leishmaniasis
by: Ricardo Evangelista Marrocos de Aragão, et al.
Published: (2015-12-01)

Urban Visceral Leishmaniasis in Venezuela
by: CM Aguilar, et al.
Published: (1998-01-01)

Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of old world cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial
by: Asilian Ali, et al.
Published: (2006-01-01)

Comparison between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-controlled, Randomized Clinical Trial
by: ALi Asilian, et al.
Published: (2012-03-01)

Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.
by: Rebecca J Faleiro, et al.
Published: (2016-02-01)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
by: Anup Bastola, et al.
Published: (2019-01-01)

Visceral leishmaniasis diagnosed by duodenal biopsy Leishmaniasis visceral diagnosticada por biopsia duodenal
by: L. del Olmo Martínez, et al.
Published: (2009-06-01)

Cryptosporidiosis in a renal transplant patient treated with paromomycin
by: ur-Rahman Khalil, et al.
Published: (2007-01-01)

Visceral leishmaniasis in AIDS patient
by: E. L. Nicodemo, et al.
Published: (1990-08-01)

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis
by: Want MY, et al.
Published: (2017-03-01)

An analysis of resistance to miltefosine and paromomycin in Leishmania donovani
by: Shaw, Craig
Published: (2016)

Leishmaniasis visceral canina
by: Bruno L. Trav
Published: (2000-01-01)

Epidemiology of visceral leishmaniasis
by: Ready PD
Published: (2014-05-01)

Immunity to Visceral Leishmaniasis
by: Nahid Ali, et al.
Published: (2012-01-01)

Visceral leishmaniasis in children
by: mandana Rafeey, et al.
Published: (2005-02-01)

Immunobiology of visceral leishmaniasis
by: Susanne eNylén, et al.
Published: (2012-08-01)